Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
China · Delayed Price · Currency is CNY 7.71
-0.18 (-2.28%)
Jun 9, 2026, 3:00 PM CST
SHA:603707 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,029 | 3,985 | 3,918 | 3,923 | 3,708 | 3,681 |
Other Revenue | 5.55 | 5.55 | 5.86 | 8.65 | 4.61 | 5.25 |
| 4,034 | 3,991 | 3,924 | 3,931 | 3,713 | 3,687 | |
Revenue Growth (YoY) | 6.04% | 1.71% | -0.20% | 5.89% | 0.71% | 26.48% |
Cost of Revenue | 2,286 | 2,238 | 2,112 | 3,272 | 1,778 | 1,603 |
Gross Profit | 1,748 | 1,753 | 1,812 | 659.14 | 1,935 | 2,083 |
Selling, General & Admin | 693.28 | 651.21 | 490.7 | 566.47 | 617.61 | 606.05 |
Research & Development | 311.72 | 348.13 | 329.92 | 372.29 | 263.66 | 220.95 |
Other Operating Expenses | 20.99 | 27.98 | 19.39 | 55.73 | 30.98 | 22.15 |
Operating Expenses | 1,033 | 1,034 | 848.23 | 991.45 | 913 | 851.58 |
Operating Income | 715.38 | 718.62 | 963.27 | -332.31 | 1,022 | 1,232 |
Interest Expense | -55.25 | -55.25 | -75.66 | -81.05 | -57.85 | -92.22 |
Interest & Investment Income | 41.04 | 46.76 | 21.96 | 27.98 | 60.74 | 27.53 |
Currency Exchange Gain (Loss) | -84.96 | -84.96 | 49.79 | 128.88 | 154.77 | 9.37 |
Other Non Operating Income (Expenses) | -11.62 | 1.41 | -6.17 | -1.35 | -0.65 | -2.74 |
EBT Excluding Unusual Items | 604.59 | 626.59 | 953.19 | -257.84 | 1,179 | 1,174 |
Gain (Loss) on Sale of Investments | 68.31 | 41.42 | -10.24 | -91.74 | -5.06 | 9.09 |
Gain (Loss) on Sale of Assets | -3.19 | -3.27 | -0.1 | -0.07 | -0.11 | -1.03 |
Asset Writedown | - | - | -8.58 | - | - | - |
Other Unusual Items | 34.67 | 34.67 | 57.76 | 54.89 | 12.02 | 21.98 |
Pretax Income | 704.38 | 699.42 | 992.03 | -294.76 | 1,185 | 1,204 |
Income Tax Expense | 118.57 | 117.91 | 165.93 | -105.31 | 98.85 | 139.84 |
Earnings From Continuing Operations | 585.81 | 581.51 | 826.1 | -189.45 | 1,087 | 1,064 |
Minority Interest in Earnings | 0.02 | 0.03 | 0.05 | 0 | 4.31 | -4.62 |
Net Income | 585.83 | 581.54 | 826.14 | -189.45 | 1,091 | 1,059 |
Net Income to Common | 585.83 | 581.54 | 826.14 | -189.45 | 1,091 | 1,059 |
Net Income Growth | -20.15% | -29.61% | - | - | 2.98% | 31.41% |
Shares Outstanding (Basic) | 1,563 | 1,615 | 1,620 | 1,579 | 1,628 | 1,581 |
Shares Outstanding (Diluted) | 1,637 | 1,615 | 1,652 | 1,579 | 1,628 | 1,581 |
Shares Change (YoY) | -2.17% | -2.23% | 4.66% | -3.03% | 2.98% | -0.43% |
EPS (Basic) | 0.37 | 0.36 | 0.51 | -0.12 | 0.67 | 0.67 |
EPS (Diluted) | 0.36 | 0.36 | 0.50 | -0.12 | 0.67 | 0.67 |
EPS Growth | -18.38% | -28.00% | - | - | - | 31.97% |
Free Cash Flow | 1,139 | 622.64 | 994.41 | 1,200 | 125.37 | 242.87 |
Free Cash Flow Per Share | 0.70 | 0.39 | 0.60 | 0.76 | 0.08 | 0.15 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.115 | 0.115 |
Dividend Growth | - | - | - | -13.04% | -0.35% | 29.95% |
Gross Margin | 43.33% | 43.92% | 46.17% | 16.77% | 52.11% | 56.51% |
Operating Margin | 17.73% | 18.01% | 24.55% | -8.45% | 27.51% | 33.41% |
Profit Margin | 14.52% | 14.57% | 21.06% | -4.82% | 29.38% | 28.73% |
Free Cash Flow Margin | 28.24% | 15.60% | 25.34% | 30.53% | 3.38% | 6.59% |
EBITDA | 970.21 | 957.46 | 1,138 | -178.25 | 1,161 | 1,325 |
EBITDA Margin | 24.05% | 23.99% | 29.01% | -4.53% | 31.27% | 35.94% |
D&A For EBITDA | 254.83 | 238.84 | 174.85 | 154.06 | 139.53 | 93.22 |
EBIT | 715.38 | 718.62 | 963.27 | -332.31 | 1,022 | 1,232 |
EBIT Margin | 17.73% | 18.01% | 24.55% | -8.45% | 27.51% | 33.41% |
Effective Tax Rate | 16.83% | 16.86% | 16.73% | - | 8.34% | 11.62% |
Revenue as Reported | 3,991 | 3,991 | 3,924 | 3,931 | 3,713 | 3,687 |